公开(公告)号：WO1998006751A1

公开(公告)日：1998-02-19

申请号：PCT/US1997014485

申请日：1997-08-18

Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  CLARK-LEWIS, Ian ,  GONG, Jiang-Hong

IPC: C07K14/52

CPC classification number: C07K14/523 ,  A61K38/00

Abstract: The present invention is directed towards NH2-terminally truncated analogs of three human chemokines: MCP-3, RANTES and MIP-1 alpha having highly potent anti-inflammatory activity and anti-autoimmune activity. The present invention is also directed to inhibiting the biological activities of three native, mammalian chemokines: MCP-3, RANTES and MIP-1 alpha . The present invention is further directed to treating inflammatory diseases and autoimmune disorders such as rheumatoid arthritis, for example. The present invention is also directed to pharmaceutical compositions comprising NH2-terminally truncated chemokine analogs.

Abstract translation: 本发明涉及三种人趋化因子的NH2-末端截短类似物：MCP-3，RANTES和MIP-1α，其具有高度有效的抗炎活性和抗自身免疫活性。 本发明还涉及抑制三种天然哺乳动物趋化因子MCP-3，RANTES和MIP-1α的生物学活性。 本发明进一步涉及治疗炎性疾病和自身免疫性疾病如类风湿性关节炎。 本发明还涉及包含NH 2 - 末端截短的趋化因子类似物的药物组合物。